|
Match
|
Document |
Document Title |
|
|
7618986 |
Method of treating latent tuberculosis
2-Nitroimidazolyl-alkylaminoquinolines, and compositions containing the same, useful in the treatment of tuberculosis are disclosed. Methods of treating tuberculosis using the...
|
|
|
7608628 |
Alkylsulphonamide quinolines
Compounds of Formula II
wherein R 1 , A, R 2 , R 3 , R 4 , R 5 , R 8 , n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical...
|
|
|
7585878 |
Benzamide derivative or salt thereof
There is provided a compound having a capsaicin receptor VR1 inhibitory activity and useful as a therapeutic agent for various pains including inflammatory pain and neurogenic pain, migraine,...
|
|
|
7576099 |
Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
Compounds are disclosed that have a formula represented by the following:
The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a...
|
|
|
7572915 |
Quinoline derivatives as phosphodiesterase inhibitors
There are provided according to the invention novel compounds of formula (I)
or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the...
|
|
|
7572806 |
PPAR active compounds
Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.
|
|
|
7566786 |
Quinoline derivatives as phosphodiesterase inhibitors
There are provided according to the invention novel compounds of formula (I)
or pharmaceutically acceptable salts thereof, wherein R 1 , R 2, R 19, R 20, and R 34 are as described in the...
|
|
|
7563804 |
FMF treatment
The method of improving FMF control, in humans, which includes administering, on an average daily basis, between 5 and 15 milligrams of LTRA to a patient suffering from FMF.
|
|
|
7560559 |
Polymorphic form of montelukast sodium
The invention provides novel polymorphic form of montelukast sodium, as well as methods of using and pharmaceutical compositions containing saud novel form. Also provided are montelukast sodium:...
|
|
|
7550483 |
Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
An amorphous form of a salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-meth
oxy-6-quinolinecarboxamide.
|
|
|
7550482 |
Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of...
|
|
|
7550481 |
Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease
The present invention is directed to phenylamide and pyridylamide derivative compounds of which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which...
|
|
|
7538221 |
Polymorphs of racemic, dextrorotatory, and levorotatory enantioners of 1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid hydrochloride and mesylate salts
A polymorphic forms of the hydrochloride salt and mesylate salt of racemic (±)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethy
lpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic...
|
|
|
7534793 |
Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
Aminopiperidine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man
|
|
|
7531554 |
4-oxoquinoline compound and use thereof as HIV integrase inhibitor
Provision of a compound having an anti-HIV activity, particularly an integrase inhibitory activity. A 4-oxoquinoline compound represented by the following formula [I] or a pharmaceutically...
|
|
|
7524862 |
Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
Alkyne compounds of formula I
wherein A, B, W, X, Y, Z, R 1 , and R 2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical...
|
|
|
7507750 |
Stabilized ascorbic acid derivative
An ascorbic acid derivative, which is a compound represented by the following general formula (1) or a salt thereof: [Chemical Formula 11]
(wherein X and Y each represents H or a protective...
|
|
|
7507749 |
Antitumor agents
The invention provides compounds of formula I:
wherein Y is F, Cl, Br, methyl or methoxy; and pharmaceutically acceptable salts thereof. The compounds are effective antitumor agent. The...
|
|
|
7504416 |
4-substituted quinolines as antitumor agents
The invention concerns compounds of formula (I), wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 8 , R 9 , R 10 m, n, p, X, Y and Z have any meanings defined in the description, processes...
|
|
|
7495104 |
Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
An objective of the present invention is to provide novel compounds which have inhibitory activity against autophosphorylation of an FGF receptor family and, when orally or intraveneously...
|
|
|
7488740 |
Substituted quinolin-4-ylamine analogues
Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the...
|
|
|
7476680 |
Substituted heterocyclic compounds for treating multidrug resistance
Compounds suitable for treating multidrug resistance and methods for their preparation and use are disclosed. The compounds are represented by the following formula:
or an optical isomer,...
|
|
|
7470709 |
Benzimidazole quinolinones and uses thereof
Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt...
|
|
|
7468379 |
Inhibition of osteolytic lesions by SRC kinase inhibitors
The present invention include methods and compositions for treating bone-resorbing diseases or bone resorption related to a pathologic condition generally, including, but not limited to...
|
|
|
7456196 |
Bicyclic-substituted amines as histamine-3 receptor ligands
Compounds of formula (I)
are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising...
|
|
|
7452887 |
Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions...
|
|
|
7449571 |
Halogenated aminoquinolines and oligonucleotides containing the same
Novel synthetic monomers that have the capacity to be assembled into defined oligomers which bind with sequence specificity to duplex Watson-Crick DNA via a triple helix motif are provided.
|
|
|
7449479 |
Hepatitis C virus inhibitors
Hepatitis C virus inhibitors are disclosed having the general formula:
wherein R 1 , R 2 , R 3 , R′, B, Y and X are described in the description.
Compositions comprising the compounds and...
|
|
|
7442710 |
Substituted phenyl methanones
The present invention relates to compounds of general formula IA or IB
wherein
X 1 and X 2 are each independently N or C—R″ and R 1 , R 2 ,R 3 , R 4 , R 5 , and R 6 are as defined in...
|
|
|
7425564 |
Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same
An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically...
|
|
|
7417148 |
4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Compounds of the formula:
wherein: n is an integer from 1-3; X is N, CH, provided that when X is N, n is 2 or 3; R is alkyl of 1 to 3 carbon atoms; R 1 is 2,4-diCl, 5-OMe; 2,4-diCl;...
|
|
|
7417056 |
5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
Compounds of general formula (IIa) or (IIb)
and their use as pharmaceutical agents.
|
|
|
7414037 |
Hydrazide-containing CFTR inhibitor compounds and uses thereof
The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and...
|
|
|
7402683 |
Cinnamic acid amides
The present invention relates to compounds, to processes for preparing them, to pharmaceutical compositions comprising them, and to their use in the therapy and/or prophylaxis in illnesses in...
|
|
|
7402674 |
7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments The invention relates to 7-phenylamino-4-quinolone-3-carboxylic acid derivatives...
|
|
|
RE40418 |
Treatment of neoplasms with CCI-779/EKB-569 combination
This invention provides the use of a combination of CCI-779 and EKB-569 in the treatment of neoplasms.
|
|
|
7384958 |
Quinoline inhibitors of cGMP phosphodiesterase
Compounds of the formula (I)
are useful as inhibitors of cGMP PDE especially Type 5.
|
|
|
7371763 |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
The invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in...
|
|
|
7365081 |
Indole derivatives and their use as medicaments
The invention relates to novel indole derivatives of the general formula 1, to their preparation and to their use as medicaments, in particular for treating tumors
|
|
|
7348340 |
N-type calcium channel antagonists for the treatment of pain
Compounds useful for the treatment of pain in accord with the following structural diagram,
wherein R 1 , R 2 and R 3 are any of a number of groups as defined in the specification and...
|
|
|
RE40155 |
Methods for treatment of benign and malignant tumors, including lymphomas, leukemias, and leiomyomas
In a preferred embodiment, drugs having chemotherapeutic properties which are useful against certain neoplastic disorders with wide safety margins as evidenced by their low toxicity, and molecular...
|
|
|
7342026 |
Substituted quinolines for the treatment of protozoa and retrovirus co-infections
The invention relates to the use of quinolines having general formula (I), wherein R 1 denotes H; alkyl C 1 -C 15 ; alkenyl or alkynyl C 2 -C 15 ; —CHO; heteroaryl; alkyl C 1 -C 15 or alkenyl...
|
|
|
7320989 |
Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.
|
|
|
7317024 |
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
The invention relates to a class of novel non-steroidal compounds which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity...
|
|
|
7312233 |
Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
Compounds are disclosed that have a formula represented by the following:
The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a...
|
|
|
7312230 |
Carboxylic acid derivatives as IP antagonists
This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I:
wherein:
R 1 , R 2 , and R 3 are each independently in each...
|
|
|
7288559 |
Carboxamide spirohydantoin CGRP receptor antagonists
The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache,...
|
|
|
7268135 |
Biaryl sulfonamides and methods for using same
The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.
|
|
|
7265130 |
NPY Y5 antagonist
The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I):
wherein R 1 is lower alkyl, cycloalkyl or the...
|
|
|
7265125 |
Neuropeptide Y antagonists
Quinoline and quinazoline derivatives can be used in the form of pharmaceutical preparations as Neuropeptide Y antagonists for the treatment or prevention of arthritis, cardiovascular diseases,...
|